In stage II-IIIA NSCLC patients with high PD-L1 expression, the benefits of atezolizumab and platinum-based chemotherapy after surgical resection appeared to be most prominent in the lobectomy subgroup according to Dr. Alessandro Brunelli and colleagues. Read more
Investigator Ticiana Leal, MD, said the the phase III LUNAR study met its primary endpoint and demonstrated a statistically significant 3-month improvement in median overall survival versus the standard of care. Read more
Dr. Roy Herbst said the results reinforce adjuvant osimertinib as the standard of care for patients with resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer and highlight the importance of early biomarker testing. Read more
During ASCO’s 2023 Annual Meeting investigators shared findings from several neoadjuvant studies, including KEYNOTE-671 and Neotorch, which showed improved EFS with pembrolizumab and toripalimab, respectively. Read more
Is “resectability” based on radical resection criteria still valid in the era of neoadjuvant immunochemotherapy? ILCN’s editors say the term needs to be revisited and probably redefined based on a tumor’s status before treatment and after neoadjuvant treatment. Read more
Presenter Dr. Alex Brunelli says neoadjuvant chemoimmunotherapy is a promising and well-tolerated treatment option in select patients with stage III NSCLC. Read more
Can radiotherapy replace surgery in stage III NSCLC in the era of immunotherapy? During ELCC 23, Dr. Sara Ramella turned to the data to answer that question. Read more
Health Canada gives greenlight to cemiplimab-chemo combo for first-line treatment of advanced NSCLC. Early registration for WCLC 23 ends June 9. Read more
Spain’s Dr. Pilar Garrido reviews long-term efficacy, safety, and predictors-of-response data for post-platinum advanced NSCLC patients with EGFR exon 20 insertion mutations. Read more
Dr. Christine Berg says both smoking and air pollution are important in causing lung cancer. And both need to be eliminated to help prevent it and save lives. Read more